• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Selecta Biosciences Inc. (Amendment)

    2/14/23 1:45:55 PM ET
    $SELB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SELB alert in real time by email
    SC 13G/A 1 mangrove-selb123122a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Selecta Biosciences, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share, including common shares obtainable upon exercise of Common Warrants

    (Title of Class of Securities)

     

    816212104

    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  816212104
     SCHEDULE 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Mangrove Partners Master Fund, Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) x
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    9,387,677(1)
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    9,387,677
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    9,387,677
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.97% (2)
    12
    TYPE OF REPORTING PERSON
     
    OO

     
    (1) Includes 4,127,258 common shares obtainable upon exercise of Common Warrants.
    (2) This percentage is calculated based on the sum of (i) 153,031,097 Shares outstanding as of November 3, 2022, based on information provided by the Issuer and (ii) 4,127,258
     


     

    CUSIP No.  816212104
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Mangrove Partners
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) x
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    9,387,677(1)(3) 
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    9,387,677
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    9,387,677
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.97% (2)
    12
    TYPE OF REPORTING PERSON
     
    OO

     
    (1) Includes 4,127,258 common shares obtainable upon exercise of Common Warrants
    (2) This percentage is calculated based on the sum of (i) 153,031,097 Shares outstanding as of November 3, 2022, based on information provided by the Issuer and (ii) 4,127,258
     


     

    CUSIP No.  816212104
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Nathaniel August
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) x
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    9,387,677(1)(3)
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    9,387,677
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    9,387,677
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.97% (2)
    12
    TYPE OF REPORTING PERSON
     
    IN, HC
     
    (1) Includes 4,127,258 common shares obtainable upon exercise of Common Warrants
    (2) This percentage is calculated based on the sum of (i) 153,031,097 Shares outstanding as of November 3, 2022, based on information provided by the Issuer and (ii) 4,127,258
     


     

     

    CUSIP No. 816212104
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Selecta Biosciences, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    65 Grove Street

    Watertown, MA 02472

    Item 2.(a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:

    Mangrove Partners, a Cayman Islands limited liability company, is located at c/o Maples Corporate Services, Ltd., PO Box 309, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands KY1-1104

    Mangrove Partners Master Fund, Ltd., a Cayman Islands limited liability company, is located at c/o Maples Corporate Services, Ltd., PO Box 309, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands KY1-1104

    Nathaniel August, a United States citizen, is located at 645 Madison Avenue, 14th Floor, New York, New York 10022

    The shares of the Issuer which are the subject of this SCHEDULE 13G/A (the “Shares”) are held by the Master Fund. Beneficial ownership of the Shares is also claimed by (i) Mangrove Partners which serves as the investment manager of the Master Fund, and (ii) Nathaniel August who is the principal of Mangrove Partners.  

     

    Item 2.(d) Title of Class of Securities

    Common Stock, $0.0001 par value per share, including common shares obtainable upon exercise of Common Warrants (the “Common Stock”)

     

    Item 2.(e) CUSIP No.:

    816212104

     

    CUSIP No.  816212104
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨

    A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                             

          Not Applicable

     

    CUSIP No. 816212104
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Information with respect to the Reporting Persons' ownership of the Common Stock as of December 31, 2022, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

    The amount beneficially owned by each Reporting Person is determined based on the sum of (i) 153,031,097 Shares outstanding as of November 3, 2022, based on information provided by the Issuer and (ii) 4,127,258 Shares issuable upon exercise of the Common Warrants, as the Issuer reported in its Form 10-Q filed with the SEC on November 3, 2022.

    The filing of this SCHEDULE 13G/A shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any of the Shares reported herein. Each of the Reporting Persons specifically disclaims beneficial ownership of the Shares reported herein that are not directly owned by such Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    See disclosures in Item 2 and Exhibit I.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 816212104
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

     

     

     

    Mangrove Partners

           
      By:  /s/ Nathaniel August
        Nathaniel August, Director
           
     

    Mangrove Partners Master Fund, Ltd

           
      By:  /s/ Nathaniel August
        Nathaniel August, Director
           
     

    Nathaniel August

           
      By:  /s/ Nathaniel August
        Nathaniel August
           

     

     
    CUSIP No. 816212104
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2023

     

     

    Mangrove Partners

           
      By:  /s/ Nathaniel August
        Nathaniel August, Director
           
     

    Mangrove Partners Master Fund, Ltd

           
      By:  /s/ Nathaniel August
        Nathaniel August, Director
           
     

    Nathaniel August

           
      By:  /s/ Nathaniel August
        Nathaniel August
           
    Get the next $SELB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SELB

    DatePrice TargetRatingAnalyst
    8/18/2023$1.00Outperform → Market Perform
    SVB Securities
    6/14/2022$6.00 → $5.00Buy
    Needham
    6/6/2022$7.00Outperform
    SVB Leerink
    11/1/2021$6.00 → $7.00Buy
    Needham
    More analyst ratings